Assessment of the safety, tolerability and immunogenicity of MV-CHIK

• Research type

  Research Study

• Full title

  Observer blinded, randomised study to investigate safety, tolerability and long-term immunogenicity of different dose regimens and formulations of MV-CHIK in healthy volunteers

• IRAS ID

  242509

• Contact name

  Mag Andrea Pfeiffer

• Sponsor organisation

  Themis Bioscience GmbH

• Eudract number

  2018-000211-25

• Duration of Study in the UK

  1 years, 1 months, days

• Research summary

  This Clinical study will investigate safety, tolerability and long-term immunogenicity of different dose regimens and formulations of MV-CHIK in 60 healthy male and female volunteers aged 18-55. MV-CHIK is a vaccine being developed to protect against Chikungunga viral infection. The study will performed at one site in the UK. Study duration per participant will be 12 months.

• REC name

  HSC REC A

• REC reference

  18/NI/0066

• Date of REC Opinion

  14 May 2018

• REC opinion

  Further Information Favourable Opinion